On April 23, 2004, a joint meeting of the FDA, NIMH, MATRICS investigators, and experts from academia and the pharmaceutical industry was convened to develop guidelines for the design of clinical trials of cognitive-enhancing drugs for neurocognitive impairments in patients with schizophrenia.

Buchanan RW, Davis M, Goff D, Green MF, Keefe RSE, Leon A, Nuechterlein K, Laughren T, Levin R, Stover E, Fenton W, Marder, S.  A Summary of the FDA-NIMH-MATRICS workshop on clinical trial designs for neurocognitive drugs for schizophrenia. Schizophrenia Bulletin, 2005; 31(1): 5-19.